Date | Price Target | Rating | Analyst |
---|---|---|---|
8/2/2024 | Outperform → Mkt Perform | Raymond James | |
3/28/2024 | $41.00 → $31.00 | Neutral → Underperform | BofA Securities |
3/7/2024 | $38.00 | Equal-Weight | Morgan Stanley |
8/24/2023 | Buy → Neutral | Citigroup | |
5/5/2023 | Mkt Perform → Outperform | Raymond James | |
1/23/2023 | $49.00 → $47.20 | Underperform → Hold | Jefferies |
11/7/2022 | Outperform → Mkt Perform | Raymond James | |
9/9/2022 | $80.00 → $61.00 | Overweight → Equal-Weight | Morgan Stanley |
Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 30 August 2024 from FMR LLC, who notified that it holds 2,687,116 of Galapagos' voting rights, consisting of 2,686,016 ordinary shares and 1,100 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Management Trust Company, Strategic Advisers LLC, and FMR Investment Management (UK) Limited, of which Fidelity Management & Research Company LLC decreased its pos
Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos' Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate produced using Galapagos' innovative decentralized cell therapy manufacturing platform with the potential for the administration of fresh, fit cells within a median vein-to-vein time of se
Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 16 August 2024 from FMR LLC, who notified that it holds 3,696,750 of Galapagos' voting rights, consisting of 3,693,550 ordinary shares and 3,200 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Management Trust Company, Strategic Advisers LLC, Fidelity Institutional Asset Management Trust Company, and FMR Investment Management (UK) Limited, of which Fid
SC 13D - GALAPAGOS NV (0001421876) (Subject)
SC 13D/A - GALAPAGOS NV (0001421876) (Subject)
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders' Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of t
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation. Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O'Day, Gilead's Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024. Mr. Dickinson joined Gilead in 2016. Prior to his current role as CFO, he served as head of the company's corporate development and strategy group. Before joining Gilead, Mr. Dickinson worked at Lazard as global c
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco
Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs.Submitted IND application to FDA for our Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101 in R/R NHL.Submitted CTA to EMA for our Phase 2 study of GLPG5201 in R/R CLL with or without RT.IND filing for our Phase 1/2 EUPLAGIA-1 study of CD19 CAR-T candidate GLPG5201 in R/R CLL with or without RT on track for Q4 2024.Encouraging new Phase 1/2 safety, efficacy, and translational data for GLPG5101 and GLPG5201, evaluating seven-day vein-to-vein, fresh CD1
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfro
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 2024Reconfirmed 2024 cash burni guidance of €280 million to €320 million, not including potential business development opportunities Webcast presentation with management on 3 May 2024, at 1
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platformInitial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical developmentAdaptimmune to receive initial payments of $100 million, comprising $70 million upfront
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatmentsImportant milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials and potential future commercial manufacturing of CAR-T therapiesComplements existing collaborations with Galapagos' other manufacturing partnersMechelen, Belgium; 15 May 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) and Blood Centers of America (BCA) today announ
Raymond James downgraded Galapagos NV from Outperform to Mkt Perform
BofA Securities downgraded Galapagos NV from Neutral to Underperform and set a new price target of $31.00 from $41.00 previously
Morgan Stanley resumed coverage of Galapagos NV with a rating of Equal-Weight and set a new price target of $38.00